The estimated Net Worth of Julia G. Butchko is at least $16.1 Millón dollars as of 21 August 2024. Dr Butchko owns over 3,027 units of Immunovant Inc stock worth over $12,809,859 and over the last 5 years he sold IMVT stock worth over $2,724,917. In addition, he makes $531,001 as Chief Devel. & Technology Officer at Immunovant Inc.
Dr has made over 24 trades of the Immunovant Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,027 units of IMVT stock worth $96,440 on 21 August 2024.
The largest trade he's ever made was selling 60,490 units of Immunovant Inc stock on 11 January 2023 worth over $1,015,627. On average, Dr trades about 5,526 units every 45 days since 2019. As of 21 August 2024 he still owns at least 440,959 units of Immunovant Inc stock.
You can see the complete history of Dr Butchko stock trades at the bottom of the page.
Dr. Julia G. Butchko Ph.D. is the Chief Devel. & Technology Officer at Immunovant Inc.
As the Chief Devel. & Technology Officer of Immunovant Inc, the total compensation of Dr D at Immunovant Inc is $531,001. There are 4 executives at Immunovant Inc getting paid more, with Peter Salzmann having the highest compensation of $8,806,830.
Dr D is 50, he's been the Chief Devel. & Technology Officer of Immunovant Inc since . There are 10 older and 5 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.
Julia's mailing address filed with the SEC is C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK, NY, 10018.
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann y Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Immunovant Inc executives and other stock owners filed with the SEC include: